サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1534092

心筋症治療の世界市場

Cardiomyopathy Therapies

出版日
ページ情報
英文 250 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
心筋症治療の世界市場
出版日: 2024年08月14日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 250 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

心筋症治療の世界市場は2030年までに34億米ドルに達する見込み

2023年に30億米ドルと推定される心筋症治療の世界市場は、2023～2030年の分析期間においてCAGR 1.7%で成長し、2030年には34億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである拡張型心筋症は、CAGR 1.9%を記録し、分析期間終了時には19億米ドルに達すると予測されます。肥大型心筋症セグメントの成長率は、分析期間中CAGR 1.4%と推定されます。

米国市場は8億2,200万米ドルと推定、中国はCAGR 3.0％で成長予測

米国の心筋症治療市場は、2023年に8億2,200万米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年にかけてCAGR 3.0%で推移し、2030年には6億2,500万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.8%と1.5%と予測されています。欧州では、ドイツがCAGR 1.1%で成長すると予測されています。

世界の心筋症治療市場- 主要動向と促進要因のまとめ

心筋症は、血液を効果的に送り出す心臓のポンプ機能を損なう複雑で異質な心筋疾患群です。これらの疾患は、拡張型、肥大型、拘束型、不整脈源性右室心筋症などいくつかのタイプに分類されます。各タイプにはそれぞれ異なる病因、病態、臨床像があり、それぞれに合った治療アプローチが必要となります。心筋症に対する現在の治療選択肢は、β遮断薬、ACE阻害薬、抗凝固薬などの薬理学的介入から、生活習慣の改善やペースメーカーや除細動器などの植え込み型デバイスの使用などの非薬理学的戦略まで多岐にわたる。重症例では、心臓再同期療法、補助人工心臓、あるいは心臓移植などの高度な治療が必要となります。様々な治療法があるにもかかわらず、心筋症は進行性で心臓突然死の可能性があるため、その管理は依然として困難です。

最近、心筋症の分子的・遺伝的基盤の解明が進み、革新的な治療法への道が開かれました。遺伝子治療と分子標的治療が研究の最前線にあり、特定の遺伝的形態の心筋症に対する治癒的解決策の可能性を提供しています。例えば、CRISPR-Cas9遺伝子編集やRNA干渉は、心筋症の原因となる欠陥遺伝子を修正または沈黙させるために研究されています。さらに、ミオシン阻害剤や選択的心筋ミオシン活性化剤などの新しい薬理学的薬剤の開発は、心収縮力を直接調節し、心機能を改善することを目的としています。幹細胞治療も有望で、現在進行中の臨床試験では、損傷した心臓組織を再生し、心筋機能を回復させる可能性が検討されています。これらの最先端治療法は、次世代シークエンシングや高度な画像診断技術を含む診断ツールの進歩によって補完され、早期かつ正確な診断が容易になり、それによってタイムリーで的を絞った介入が可能になります。

心筋症治療市場の成長は、いくつかの要因によって牽引されています。心血管疾患の有病率の上昇、特に高齢化により、効果的な心筋症治療に対する需要が大幅に増加しています。診断および治療方法の技術的進歩により、利用可能な治療選択肢の幅が広がり、より個別化された効果的な治療を提供することが可能になった。患者や医療従事者の心筋症に対する認識と理解の向上は、早期診断と早期介入につながり、患者の転帰を改善しています。さらに、製薬会社や学術機関による研究開発への多額の投資により、新規治療法の発見と商業化が加速しています。また、多くの地域における政府の支援政策や有利な償還の枠組みも、より多くの患者が先進的な治療にアクセスできるようにする上で重要な役割を果たしています。さらに、遠隔モニタリングや遠隔医療などのデジタルヘルス技術の統合は、患者管理と治療へのアドヒアランスを強化し、市場の成長を促進しています。これらの要因が相まって、心筋症治療市場はダイナミックかつ急速に発展しています。

調査対象企業の例（全86件）

  • Abbott Cardiovascular
  • Alexion Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bio-Rad Laboratories, Inc.
  • Bristol Myers Squibb company
  • Cardiol Therapeutics, Inc.
  • Cipla Ltd
  • Cytokinetics, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Diagnostics（Schweiz）AG
  • Tenaya Therapeutics;

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP26852

Global Cardiomyopathy Therapies Market to Reach US$3.4 Billion by 2030

The global market for Cardiomyopathy Therapies estimated at US$3.0 Billion in the year 2023, is expected to reach US$3.4 Billion by 2030, growing at a CAGR of 1.7% over the analysis period 2023-2030. Dilated Cardiomyopathy, one of the segments analyzed in the report, is expected to record a 1.9% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the Hypertrophic Cardiomyopathy segment is estimated at 1.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$822.0 Million While China is Forecast to Grow at 3.0% CAGR

The Cardiomyopathy Therapies market in the U.S. is estimated at US$822.0 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$625.0 Million by the year 2030 trailing a CAGR of 3.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 1.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.1% CAGR.

Global Cardiomyopathy Therapies Market - Key Trends and Drivers Summarized

Cardiomyopathy is a complex and heterogeneous group of heart muscle diseases that impair the heart's ability to pump blood effectively. These conditions can be classified into several types, including dilated, hypertrophic, restrictive, and arrhythmogenic right ventricular cardiomyopathy. Each type has distinct etiologies, pathophysiologies, and clinical presentations, necessitating tailored therapeutic approaches. Current treatment options for cardiomyopathy range from pharmacological interventions such as beta-blockers, ACE inhibitors, and anticoagulants, to non-pharmacological strategies, including lifestyle modifications and the use of implantable devices like pacemakers and defibrillators. In severe cases, patients may require advanced therapies such as cardiac resynchronization therapy, ventricular assist devices, or even heart transplantation. Despite the variety of treatments available, managing cardiomyopathy remains challenging due to its progressive nature and the potential for sudden cardiac death.

Recent advancements in the understanding of molecular and genetic underpinnings of cardiomyopathy have paved the way for innovative therapeutic approaches. Gene therapy and molecular-targeted therapies are at the forefront of research, offering potential curative solutions for certain genetic forms of cardiomyopathy. For instance, CRISPR-Cas9 gene editing and RNA interference are being explored to correct or silence defective genes responsible for cardiomyopathy. Additionally, the development of novel pharmacological agents, such as myosin inhibitors and selective cardiac myosin activators, is aimed at directly modulating cardiac contractility and improving heart function. Stem cell therapy also holds promise, with ongoing clinical trials investigating its potential to regenerate damaged heart tissue and restore myocardial function. These cutting-edge therapies are complemented by advancements in diagnostic tools, including next-generation sequencing and advanced imaging techniques, which facilitate early and precise diagnosis, thereby enabling timely and targeted interventions.

The growth in the cardiomyopathy therapies market is driven by several factors. The rising prevalence of cardiovascular diseases, particularly in aging populations, has significantly increased the demand for effective cardiomyopathy treatments. Technological advancements in diagnostic and therapeutic modalities have expanded the range of available treatment options, making it possible to offer more personalized and effective care. Increased awareness and understanding of cardiomyopathy among patients and healthcare providers have led to earlier diagnosis and intervention, improving patient outcomes. Furthermore, substantial investments in research and development by pharmaceutical companies and academic institutions are accelerating the discovery and commercialization of novel therapies. Supportive government policies and favorable reimbursement frameworks in many regions are also playing a crucial role in making advanced treatments accessible to a broader patient population. Additionally, the integration of digital health technologies, such as remote monitoring and telemedicine, is enhancing patient management and adherence to therapy, thereby driving market growth. Collectively, these factors are fostering a dynamic and rapidly evolving market for cardiomyopathy therapies.

Select Competitors (Total 86 Featured) -

  • Abbott Cardiovascular
  • Alexion Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bio-Rad Laboratories, Inc.
  • Bristol Myers Squibb company
  • Cardiol Therapeutics, Inc.
  • Cipla Ltd
  • Cytokinetics, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Diagnostics (Schweiz) AG
  • Tenaya Therapeutics;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Cardiomyopathy Therapies - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Cardiovascular Diseases Spurs Demand for Cardiomyopathy Therapies
    • Technological Advancements in Diagnostic Modalities Propel Growth
    • Gene Therapy and Molecular-Targeted Treatments Expand Addressable Market Opportunity
    • Increased Awareness and Early Diagnosis Strengthen Business Case for Innovative Therapies
    • Development of Novel Pharmacological Agents Generates New Market Opportunities
    • Here's How Advancements in Stem Cell Therapy Drive Market Dynamics
    • Growing Focus on Personalized Medicine Drives Adoption of Tailored Treatment Approaches
    • Integration of Digital Health Technologies Sustains Growth in Patient Management
    • Expansion of Telemedicine Services Enhances Access to Cardiomyopathy Care
    • Rising Geriatric Population Throws the Spotlight On Need for Comprehensive Cardiac Care
    • Here's the Story: Impact of Advanced Imaging Techniques on Early and Accurate Diagnosis
    • Evolution of Multimodal Treatment Strategies Drives Comprehensive Patient Care
    • Advances in Biomarker Discovery Generate Opportunities for Precision Medicine
    • Trend towards Outpatient Cardiac Care Spurs Demand for Non-Invasive Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cardiomyopathy Therapies Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Cardiomyopathy Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Cardiomyopathy Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Dilated Cardiomyopathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Dilated Cardiomyopathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Dilated Cardiomyopathy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hypertrophic Cardiomyopathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Hypertrophic Cardiomyopathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Hypertrophic Cardiomyopathy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: USA 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: Canada 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • JAPAN
    • Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: Japan 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • CHINA
    • Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: China 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • EUROPE
    • Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Cardiomyopathy Therapies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Cardiomyopathy Therapies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • FRANCE
    • Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: France 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • GERMANY
    • Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Germany 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Italy 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: UK 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 44: Spain Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Spain Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Spain 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 47: Russia Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Russia Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Russia 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Rest of Europe Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Rest of Europe 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Cardiomyopathy Therapies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Cardiomyopathy Therapies by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 59: Australia Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Australia Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Australia 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • INDIA
    • Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 62: India Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: India Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: India 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 65: South Korea Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: South Korea Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: South Korea 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Rest of Asia-Pacific Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Rest of Asia-Pacific 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Cardiomyopathy Therapies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Cardiomyopathy Therapies by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 77: Argentina Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Argentina Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Argentina 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 80: Brazil Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Brazil Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Brazil 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 83: Mexico Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Mexico Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Mexico 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Latin America Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Rest of Latin America 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Cardiomyopathy Therapies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Cardiomyopathy Therapies by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 95: Iran Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Iran Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Iran 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 98: Israel Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Israel Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Israel 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Saudi Arabia Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Saudi Arabia 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 104: UAE Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: UAE Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: UAE 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Rest of Middle East Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Rest of Middle East 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030
  • AFRICA
    • Cardiomyopathy Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 110: Africa Recent Past, Current & Future Analysis for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Africa Historic Review for Cardiomyopathy Therapies by Disease Type - Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Africa 16-Year Perspective for Cardiomyopathy Therapies by Disease Type - Percentage Breakdown of Value Sales for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy and Other Disease Types for the Years 2014, 2024 & 2030

IV. COMPETITION